Optimizing LDL-C Reduction in Lipid Management: What Managed Care Needs to Know about Reducing Major CV Risks with New and Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2023 to March 1, 2024

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation

Over 73 million adults in the United States have hypercholesterolemia and are at elevated risk for atherosclerotic cardiovascular disease. Low-density lipoprotein cholesterol (LDL-C) is a primary mediator of the development of heart disease and plays a key role in determining cardiovascular risk and overall health management. Early and aggressive lowering of LDL-C reduces the risk of atherosclerotic cardiovascular disease (ASCVD) events in patients with hypercholesterolemia, and every 1.0 mmol/L reduction in LDL-C is estimated to lead to ~20% reduction in the relative risk of major cardiovascular events. Statins are the mainstay of hypercholesterolemia management, but many patients do not tolerate statin-based treatment, which ultimately leads to medication nonadherence, ASCVD events, and higher healthcare costs. On the other hand, some patients, including those with pre-existing ASCVD or severe hypercholesterolemia, do not reach recommended LDL-C treatment targets despite intensive statin therapy. Non-statin agents can be useful for patients who inadequately respond to or are intolerant of statin therapy. Fortunately for patients with high LDL-C, several new treatments have recently become available as an adjunct or instead of statin therapies. These options, including agents that inhibit production of PCSK9, that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.

Upon completion of this activity, participants will be able to:

  • Describe the clinical and economic consequences of patient non-adherence and clinical inertia on ASCVD event risk in patients with hypercholesterolemia

  • Recognize the benefits of early, aggressive lipid-lowering strategies that target absolute LDL-C reduction in patients who are at high risk for or who have ASCVD

  • Compare and contrast efficacy, safety, and dosing/administration profiles of novel therapeutics that lower LDL-C in lipid management, including PCSK9 inhibitors, in a range of patient populations

  • Examine the role of siRNA-based inhibition of PCSK9 in managing patients with hypercholesterolemia or ASCVD

  • Identify patients who may benefit from PCSK9 inhibition in place of or as an adjunct to statin therapy

  • Assess the managed care considerations of newer PCSK9 inhibitors, by exploring where these agents may fit into the current lipid management paradigm


Faculty: Michael Miller, MD
Cardiologist & Chief of Medicine
Corporal Michael J Crescenz VA Medical Center
Vice Chair of Medicine
Hospital of the University of Pennsylvania


(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Miller has no relevant financial relationship with an ineligible company to disclose.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue